459 related articles for article (PubMed ID: 20848588)
21. The Sirtuin family: therapeutic targets to treat diseases of aging.
Milne JC; Denu JM
Curr Opin Chem Biol; 2008 Feb; 12(1):11-7. PubMed ID: 18282481
[TBL] [Abstract][Full Text] [Related]
22. [Sirtuins--modulation of their activity as a novel therapeutic target].
Kucińska M; Piotrowska H; Murias M
Pol Merkur Lekarski; 2010 Mar; 28(165):231-5. PubMed ID: 20815175
[TBL] [Abstract][Full Text] [Related]
23. Sirtuins and p53.
van Leeuwen I; Lain S
Adv Cancer Res; 2009; 102():171-95. PubMed ID: 19595309
[TBL] [Abstract][Full Text] [Related]
24. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1.
Kelly G
Altern Med Rev; 2010 Sep; 15(3):245-63. PubMed ID: 21155626
[TBL] [Abstract][Full Text] [Related]
25. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults.
Okawara M; Katsuki H; Kurimoto E; Shibata H; Kume T; Akaike A
Biochem Pharmacol; 2007 Feb; 73(4):550-60. PubMed ID: 17147953
[TBL] [Abstract][Full Text] [Related]
26. Seven sirtuins for seven deadly diseases of aging.
Morris BJ
Free Radic Biol Med; 2013 Mar; 56():133-71. PubMed ID: 23104101
[TBL] [Abstract][Full Text] [Related]
27. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2.
Kelly GS
Altern Med Rev; 2010 Dec; 15(4):313-28. PubMed ID: 21194247
[TBL] [Abstract][Full Text] [Related]
28. Sirtuins: novel targets for metabolic disease in drug development.
Jiang WJ
Biochem Biophys Res Commun; 2008 Aug; 373(3):341-4. PubMed ID: 18577374
[TBL] [Abstract][Full Text] [Related]
29. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing.
Trapp J; Jung M
Curr Drug Targets; 2006 Nov; 7(11):1553-60. PubMed ID: 17100594
[TBL] [Abstract][Full Text] [Related]
30. Sirtuins: novel targets for metabolic disease.
Elliott PJ; Jirousek M
Curr Opin Investig Drugs; 2008 Apr; 9(4):371-8. PubMed ID: 18393104
[TBL] [Abstract][Full Text] [Related]
31. 9-Fluorenylmethoxycarbonyl-labeled peptides as substrates in a capillary electrophoresis-based assay for sirtuin enzymes.
Fan Y; Ludewig R; Scriba GK
Anal Biochem; 2009 Apr; 387(2):243-8. PubMed ID: 19454228
[TBL] [Abstract][Full Text] [Related]
32. Sirtuin activators and inhibitors.
Villalba JM; Alcaín FJ
Biofactors; 2012; 38(5):349-59. PubMed ID: 22730114
[TBL] [Abstract][Full Text] [Related]
33. Current Trends in Sirtuin Activator and Inhibitor Development.
Bursch KL; Goetz CJ; Smith BC
Molecules; 2024 Mar; 29(5):. PubMed ID: 38474697
[TBL] [Abstract][Full Text] [Related]
34. Function of sirtuins in biological tissues.
Shoba B; Lwin ZM; Ling LS; Bay BH; Yip GW; Kumar SD
Anat Rec (Hoboken); 2009 Apr; 292(4):536-43. PubMed ID: 19301279
[TBL] [Abstract][Full Text] [Related]
35. Neuronal protection by sirtuins in Alzheimer's disease.
Anekonda TS; Reddy PH
J Neurochem; 2006 Jan; 96(2):305-13. PubMed ID: 16219030
[TBL] [Abstract][Full Text] [Related]
36. Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications.
Cen Y; Youn DY; Sauve AA
Curr Med Chem; 2011; 18(13):1919-35. PubMed ID: 21517779
[TBL] [Abstract][Full Text] [Related]
37. Sirtuins: the future insight.
Suvarna BS
Kathmandu Univ Med J (KUMJ); 2012; 10(38):77-82. PubMed ID: 23132482
[TBL] [Abstract][Full Text] [Related]
38. Promising drug discovery strategies for sirtuin modulators: what lessons have we learnt?
Garg G; Singh AK; Singh S; Rizvi SI
Expert Opin Drug Discov; 2021 Aug; 16(8):915-927. PubMed ID: 33880981
[TBL] [Abstract][Full Text] [Related]
39. Medicine. The yin-yang of sirtuins.
Dillin A; Kelly JW
Science; 2007 Jul; 317(5837):461-2. PubMed ID: 17656709
[No Abstract] [Full Text] [Related]
40. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension.
Porcu M; Chiarugi A
Trends Pharmacol Sci; 2005 Feb; 26(2):94-103. PubMed ID: 15681027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
